Name (Synonyms) | Correlation | |
---|---|---|
drug295 | Exercise brochure Wiki | 0.50 |
drug244 | DAS181 OL Wiki | 0.50 |
drug422 | Inhaled beclomethasone Wiki | 0.50 |
drug243 | DAS181 COVID-19 Wiki | 0.50 |
drug269 | Doxycycline Wiki | 0.35 |
drug826 | Telerehabilitation Wiki | 0.25 |
drug650 | Presatovir Wiki | 0.25 |
drug616 | Placebo Wiki | 0.21 |
Name (Synonyms) | Correlation | |
---|---|---|
D018184 | Paramyxoviridae Infections NIH | 0.29 |
D018357 | Respiratory Syncytial Virus Infections NIH | 0.25 |
D003141 | Communicable Diseases NIH | 0.24 |
D007251 | Influenza, Human NIH | 0.19 |
D007239 | Infection NIH | 0.17 |
D012141 | Respiratory Tract Infections NIH | 0.13 |
D014777 | Virus Diseases NIH | 0.11 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0011947 | Respiratory tract infection HPO | 0.20 |
There are 4 clinical trials
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Description: Removal of all oxygen support (with stable SpO2)
Measure: Percent of subjects who Return to Room Air (RTRA) (main study) Time: by Day 28This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.
Description: Percent of subjects who have returned to room air
Measure: Percent of subjects who have returned to room air Time: 7 daysDescription: Percent change of subjects return to baseline oxygen requirement by Day 7 compared to Day 1
Measure: Percent change of subjects return to baseline oxygen requirement Time: 7 daysThe objective of the study is to investigate the safety and potential efficacy of DAS181 for the treatment of severe COVID-19.
Description: Percent of subjects with improved clinical status
Measure: Improved clinical status Time: Day 14Description: Percent of subjects return to room air
Measure: Return to room air Time: Day 14Description: time to SARS-CoV-2 RNA in the respiratory specimens being undetectable
Measure: SARS-CoV-2 RNA Time: 28 daysDescription: Percent of patients discharge from hospital
Measure: Discharge Time: Days 14, 21, 28Description: All-cause mortality rate
Measure: Death Time: Day 14, 21, 28It is a multicenter, randomized, placebo-controlled, double-blind study. The study population is defined as subjects diagnosed with lower respiratory tract COVID-19 who require supplemental oxygen ≥2 LPM at the time of randomization.
Description: Percent of subjects improved (1 to 7 where higher score means worse outcome)
Measure: COVID-19 Clinical Status Scale (CCSS) Time: Day 14Description: Clinical Status Scale 1 to 7 (where higher score means worse outcome)
Measure: Clinical Status Scale Time: Day 28Description: Percent of subjects RTRA
Measure: Return To Room Air (RTRA) Time: Day 10, 14, 21, 28Description: Time tov
Measure: Death (all cause) Time: Day 28Description: Time to
Measure: SARS-CoV-2 RNA undetectable Time: Day 28Description: Percent of subjects discharge
Measure: Percent of subjects discharged Time: Day 14, 21, 28